Indoco Remedies gets USFDA nod for Succinylcholine Chloride Injection

The product is being used for some patients infected with Coronavirus (COVID-19)

Published On 2020-05-27 06:17 GMT   |   Update On 2020-05-27 06:17 GMT

Mumbai: Indoco Remedies has received USFDA approval for Succinylcholine Chloride Injection, USP 200 mg / 10 ml (20 mg/ml) multi-dose vial, therapeutically equivalent to the Reference Listed Drug (RLD) Quelicin Injection of Hospira, Inc.

Succinylcholine Chloride Injection is indicated as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

The US market size of Succinylcholine Chloride Injection is 72 million USD (6 million vials), as per IMS data for the year ending March 2020.

The product is being used for some patients infected with Coronavirus (COVID-19).

Commenting on this positive outcome, Ms. Aditi Kare Panandikar, Managing Director – Indoco Remedies Ltd. said, "The receipt of this USFDA approval, in a record time of just 4 months from the date of filing ANDA, is very encouraging. It brings an enormous opportunity to Indoco to serve the patients in these trying times."

Read also: COVID 19: Natco Pharma supports Columbia University trials for CQ tablets to prevent infections


Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News